Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status Meeting Abstract

  

Authors:	Gillen, J.; Miller, A.; Moore, K. N.; Bell-McGuinn, K. M.; Schilder, R.; Walker, J. L.; Brady, W. E.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; Hagemann, A. R.; Gray, H. J.; Duska, L. R.; Mathews, C. A.; Chen, A.; O'Malley, D. M.; Gordon, S. W.; Fracasso, P. M.; Aghajanian, C.
Abstract Title:	Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status
Meeting Title:	51st Annual Meeting of the Society of Gynecologic Oncology (SGO)
Journal Title:	Gynecologic Oncology
Volume:	159
Issue:	Suppl. 1
Meeting Dates:	2020 Mar 28-31
Meeting Location:	Toronto, Canada
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2020-10-01
Start Page:	15
End Page:	16
Language:	English
ACCESSION:	WOS:000579556200028
DOI:	10.1016/j.ygyno.2020.06.029
PROVIDER:	wos
Notes:	Meeting Abstract: 28 -- This meeting was cancelled due to COVID-19 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/173873